Treatment algorithm. Treatment algorithm. IPAH: idiopathic pulmonary arterial hypertension; APAH: associated pulmonary arterial hypertension; WHO-FC: World.

Slides:

Advertisements

Similar presentations

Guidelines for the diagnosis and treatment of pulmonary hypertension by, Nazzareno Galiè, Marius M. Hoeper, Marc Humbert, Adam Torbicki, Jean-Luc Vachiery,

Advertisements

Pulmonary Hypertension and Various Treatment Options

PULMONARY ARTERIAL HYPERTENSION (PAH)

PULMONARY HYPERTENSION

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pulmonary Arterial Hypertension J Am Coll Cardiol.

Hypertension treatment guidelines from the United Kingdom’s National Institute for Health and Care Excellence. Guidelines identify angiotensin-converting.

Pulmonal hypertensjon

Evidence-based treatment algorithm, including clinical trials published through A, B, and C are levels of evidence defined as follows—Level of Evidence:

Clinical use of PAH drugs based on functional class

Subclinical organ damage Treatment LVH

Endothelium-derived mediators: the vasodilators prostacyclin (PGI2) and nitric oxide (NO) and the vasoconstrictor endothelin (ET-1). Endothelium-derived.

UNDERSTANDING RISK STRATIFICATION IN PAH:

The key pathways and classes of drugs that have been approved for the treatment of pulmonary arterial hypertension. The key pathways and classes of drugs.

Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.

Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients Gérald Simonneau, Nazzareno Galiè,

Current and Emerging Data in CTEPH

Decision tree of the FALLS protocol.

Idiopathic Pulmonary Arterial Hypertension in Asians

Pulmonary Hypertension after Hematopoietic Stem Cell Transplantation

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016 Murray Epstein, MD, Daniel A. Duprez,

Diagnostic algorithm. Diagnostic algorithm. PH: pulmonary hypertension; group: clinical group; TTE: transthoracic echocardiography; PFT: pulmonary function.

Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018 Marius M. Hoeper, Christian Apitz,

Plexiform lesion from a patient with severe pulmonary hypertension demonstrating the exuberant proliferation of cells that comprise the lumen of the small.

Schematic diagram showing as yet unexplored pathophysiological mechanisms in pulmonary arterial hypertension (PAH). Schematic diagram showing as yet unexplored.

PRISMA study flow diagram

Key pathways involved in the pathogenesis of pulmonary arterial hypertension: a) endothelin (ET) pathway; b) nitric oxide pathway; and c) prostacyclin.

REVEAL pulmonary arterial hypertension (PAH) risk score.

The key pathological mechanisms underlying vascular changes in pulmonary hypertension (PH). The key pathological mechanisms underlying vascular changes.

Forest plot showing the number of adults (at the top) and children (lower down) who were admitted to hospital after treatment in the emergency department.

Timeline of approval of therapies for pulmonary arterial hypertension.

Treatment algorithm for managing chronic thromboembolic pulmonary hypertension (CTEPH), from the European Society of Cardiology/European Respiratory Society.

An algorithm for the early diagnosis of pulmonary arterial hypertension in systemic sclerosis. An algorithm for the early diagnosis of pulmonary arterial.

Guo-Wei He, MD, DSc, David P. Taggart, FRCS

An expert proposal for a treat-to-target checklist for pulmonary arterial hypertension (PAH). An expert proposal for a treat-to-target checklist for pulmonary.

Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.

Pathophysiology of right ventricular (RV) failure.

Simplified REVEAL (Registry to Evaluate Early And Long-term PAH Disease Management) risk score. Simplified REVEAL (Registry to Evaluate Early And Long-term.

Effect of intravenous furosemide in a pulmonary arterial hypertension patient admitted with overt right heart failure documented by echo-Doppler of the.

Elastic staining of paraffin-embedded lung tissue.

The changing distribution of endothelin (ET)A and ETB subtypes with decreasing vessel diameter. a) ET-1 binding and b) distribution of ETA and ETB receptors.

Mean change from baseline in 6-min walking distance (6MWD) in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial.

Proteinase activated receptor-1 expression in a) weak immunostaining in normal lung tissue, b) intense immunostaining in idiopathic pulmonary fibrosis,

Kaplan–Meier curves for the probability of a first adjudicated primary end-point event in the AMBITION trial, suggesting that the primary outcome events.

Survival in patients with pulmonary arterial hypertension based on aetiology. •: congenital heart disease; ▪: collagen vascular disease; ▵: HIV-related;

Right ventricular (RV) pressure–volume loops at decreasing venous return in a patient with a) systemic sclerosis-associated pulmonary arterial hypertension.

Incidence of chronic obstructive pulmonary disease according to the history of chronic cough/phlegm. Incidence of chronic obstructive pulmonary disease.

Proportion of patients in each World Health Organization functional class (WHO-FC) at the time of pulmonary arterial hypertension-associated systemic sclerosis.

Mechanism of action for pulmonary arterial hypertension medications.

Pulmonary arterial hypertension specific medication use at enrolment among previously diagnosed patients. 184 (7%) of patients were not on a prostaglandin,

Cardiac magnetic resonance imaging of the heart in a patient with pulmonary arterial hypertension. a) Short axis image. #: dilated right ventricle; ¶:

Survival of idiopathic pulmonary arterial hypertension (IPAH) patients in World Health Organization functional class (FC) at baseline IV is extremely poor.

Kaplan–Meier plots for a) clinical worsening and b) survival in the overall population during the Chronic Thromboembolic Pulmonary Hypertension Soluble.

A) Pulmonary arterial hypertension (PAH) aetiological breakdown of REVEAL patients at enrolment. b) Breakdown of associated PAH subgroup. a) Pulmonary.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (○) 1 mg and 2.5 mg compared with inhaled nitric oxide (•) in patients.

Distribution of systolic pulmonary artery pressure (Ppa) in relation to functional class (FC) for congenital heart disease patients with a) atrial septal.

Algorithm for haemodynamic evaluation in the elderly.

Effect of riociguat on a) right heart hypertrophy (assessed by the ratio of right ventricle weight to left ventricle and septum weight (RV/(LV+S)) and.

Survival rates in older (>65 years) compared with younger (18–65 years) patients with idiopathic pulmonary arterial hypertension. a) Expected ( )

Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification based on symptom and risk evaluation. a) GOLD model of symptom/risk evaluation.

Compounds acting on pathogenic pathways of pulmonary arterial hypertension. Compounds acting on pathogenic pathways of pulmonary arterial hypertension.

The European population from 1950 to 2050, with estimated population before 2006 (light background) and projected population (dark background). The European.

Effect of pulmonary arterial hypertension-specific treatment on systemic inflammation. a) Kaplan–Meyer survival curves for patients normalising their C-reactive.

Drugs that target the prostacyclin pathway and their routes of administration. #: approved only by the US Food and Drug Administration; ¶: approved only.

Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.

Treatment algorithm for DCM/PPCM, HCM and RCM during pregnancy and after delivery. Treatment algorithm for DCM/PPCM, HCM and RCM during pregnancy and after.

Treatment algorithm for chronic thromboembolic pulmonary hypertension.

Real-life pulmonary arterial hypertension (PAH) patient cases to reflect the importance of a collaborative approach to patient engagement. Real-life pulmonary.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (Rio) compared with inhaled nitric oxide (NO) in patients with chronic.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Presentation transcript:

Treatment algorithm. Treatment algorithm. IPAH: idiopathic pulmonary arterial hypertension; APAH: associated pulmonary arterial hypertension; WHO-FC: World Health Organization functional class; CCB: calcium channel blockers; FDA: US Food and Drug Administration; CHMP: Committee for Medicinal Products for Human Use; EMA: European Medicines Agency; s.c.: subcutaneous; ERA: endothelin receptor antagonist; PDE-5i: phosphodiesterase type 5 inhibitor; sGCS: soluble guanylate cyclase stimulators; BAS: balloon atrial septostomy. Reproduced from [14] with permission from the publisher. Victor J. Samillan, and Andrew J. Peacock Breathe 2014;10:188-197 ©2014 by European Respiratory Society